Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at ...

Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after ...

New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Detection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responsesData further underlines the strong ...

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ...
BioSpace

Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially ...
Nature

Checkpoint inhibitor combinations: the trial-to-approval gap

Immune checkpoint inhibitors (CPIs) have transformed cancer treatment, but resistance and limited response rates have driven ...
BioSpace

Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback

Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...
Business Wire

Rivia Expands Clinical Trial Intelligence Platform with New AI-Powered Data Findings Module

Rivia Expands Clinical Trial Intelligence Platform with New AI-Powered Data Findings Module New module enables continuous, automated review of clinical trial data, helping drug developers identify ...
BIOENGINEER

Review Analyzes Olive Phenol Hydroxytyrosol Across Cellular Pathways and Clinical Trials

A systematic review examines the cellular mechanisms, pharmacokinetic limitations, and available clinical evidence for the ...

Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology ...

BEACON Trial Results Selected for Official ASH Press ProgramInitial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in ...

Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study

WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...